E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Immunogenicity Objective
To evaluate the antibody response to each influenza vaccine antigen after vaccination with the aTIV vaccine, as measured by single radial hemolysis (SRH) or hemagglutination inhibition (HI) assay in accordance with Guidance CPMP/BWP/214/96
Safety Objective
To evaluate the safety of aTIV in adult subjects ≥65 years of age in compliance with the requirements of the current European Union recommendations for clinical trials related to yearly licensing of influenza vaccines (CPMP/BWP/214/96)
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In order to participate in this study, a subject must meet ALL of the following inclusion criteria:
▫ Is a male or female volunteer ages 65 years or older, mentally competent, willing and able to give written informed consent prior to study entry;
▫ Is able to comply with all the study requirements; and
▫ Is in good health as determined by the outcome of medical history, physical examination, and clinical judgment of the investigator
|
|
E.4 | Principal exclusion criteria |
In order to participate in this study, a subject must not meet any of the following exclusion criteria:
▫ Has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject’s ability to participate in the study;
▫ Has a serious chronic or acute disease (in the judgment of the investigator) including, but not limited to
- medically significant cancer (except for benign or localized skin cancer, cancer in remission for ≥10 years, or localized prostate cancer that has been clinically stable for >2 years without treatment)
- medically significant advanced congestive heart failure (ie, New York Heart Association [NYHA] class III and IV)
- chronic obstructive pulmonary disease (ie, Global initiative for chronic Obstructive Lung Disease [GOLD] stage III and IV)
- autoimmune disease (including rheumatoid arthritis and excepting Hashimoto’s thyroiditis that has been clinically stable for ≥5 years)
- diabetes mellitus type I
- poorly controlled diabetes mellitus type II
- advanced arteriosclerotic disease
- history of underlying medical condition such as major congenital abnormalities requiring surgery, chronic treatment, or associated with developmental delay (eg, Down’s syndrome)
- acute or progressive hepatic disease
- acute or progressive renal disease
- severe neurological (especially Guillain–Barré syndrome) or psychiatric disorder
- severe asthma
▫ Has a history of any anaphylactic reaction and/or serious allergic reaction to any component of the study vaccine (see section 5.1);
▫ Has a known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:
- receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study,
- receipt of immunostimulants within the past 6 months,
- receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within the past 3 months and for the full length of the study, or
- suspected or known human immunodeficiency virus (HIV) infection or HIV related disease
▫ Has known or suspected drug or alcohol abuse within the past 2 years;
▫ Has bleeding diathesis or conditions associated with prolonged bleeding time that, in the investigator’s opinion, would interfere with the safety of the subject;
▫ Is not able to comprehend and to follow all required study procedures for the whole period of the study;
▫ Has a history or any illness that, in the opinion of the investigator, would pose additional risk to the subjects because of participation in the study;
▫ Has the following within the past 6 months:
- had any laboratory confirmed seasonal or pandemic influenza disease
- received any seasonal or pandemic influenza vaccine
▫ Has received any other vaccine within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine during the study;
▫ Has acute or chronic infections requiring antiviral therapy within the last 7 days;
▫ Has experienced fever (ie, body temperature [preferably oral] ≥38.0°C) within the last 3 days of intended study vaccination;
▫ Has been participating in any clinical trial with another investigational product 4 weeks prior to first study visit or intends to participate in another clinical study at any time during the conduct of this study;
▫ Is part of study personnel or has close family members conducting this study;
▫ Has a body mass index (BMI) >35 kg/m2 (BMI is calculated by dividing the subject’s weight in kilograms by the subject’s height in meters multiplied by the subject’s height in meters).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immunogenicity Endpoints:
Antibody responses will be evaluated by the SRH assay according to the following endpoints:
▫ The percentage of subjects with SRH area ≥25 mm2
▫ The percentage of subjects achieving seroconversion or significant increase by SRH area
- Seroconversion is defined as day 1 SRH area with a negative result (SRH area ≤4 mm2) and day 22 ( 1/+3) SRH area ≥25 mm2
- Significant increase is defined as a positive day 1 SRH area (SRH area >4 mm2) and at least a 50% increase in SRH area on day 22 ( 1/+3)
▫ Geometric mean ratio (GMR) day 22 ( 1/+3)/day 1
Antibody responses will be evaluated by the HI assay according to the following endpoints:
▫ The percentage of subjects with HI titer ≥1:40
▫ The percentage of subjects achieving seroconversion or significant increase in HI titer
- Seroconversion is defined as day 1 HI titer <1:10 and day 22 ( 1/+3) HI titer ≥1:40
- Significant increase is defined as day 1 HI titer ≥1:10 and at least a 4-fold increase in HI titer on day 22 ( 1/+3)
▫ GMR day 22 ( 1/+3)/day 1
Safety Endpoints:
Safety endpoints are based on solicited and unsolicited AEs.
The measures for assessing safety are as follows:
▫ Percentages of subjects with solicited local and systemic AEs and other solicited events as measured for 4 days (day 1 through day 4, inclusive) following vaccination
- Calculated for 2 time intervals after vaccination: 30 minutes, day 1 (after 6 hours) through day 4 (inclusive, ie, excluding the observations at 30 minutes)
▫ Percentages of subjects with any unsolicited AEs reported for 4 days (day 1 through day 4, inclusive) following vaccination
▫ Percentages of subjects reporting unsolicited SAEs, medically attended AEs, AEs leading to withdrawal from the study, and concomitant medications/vaccinations associated with these events as collected from day 1 through day 22 ( 1/+3)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
• Immunogenicity 21 days after vaccination
• Solicited and Unsolicited AEs will be assessed for 3 days post the day of vaccination
• AEs Days 1 to 4. From Day 5 to study end AEs necessitating a physician's visit or consultation and/or leading to premature study discontinuation and SAEs. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 22 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |